Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Wen et al. (posted on 31/3/2020)


Wen et al aimed to characterise the immune cell composition and transcriptional changes of peripheral blood mononuclear cells (PBMCs) in patients in early and late recovery stages of COVID-19. On all samples, they performed single cell RNA-sequencing (10x) with additional TCR and BCR sequencing. They identified an inflammatory immune signature in the early recovery stage (ERS) with an accumulation of inflammatory monocytes. By pinpointing specific BCR changes, they provide a framework for potential vaccine design. Using a not well-established computational approach to predict cell-cell interactions, they claim an ‘inflammatory storm’ where inflammatory monocytes act as pivoting members in the ERS.

Research highlights

  1. Immune response is sustained more than 7 days after testing negative for COVID-19
  2. Increased fraction of classical inflammatory monocytes (CD14++ IL1b+) in peripheral blood of post-COVID-19 infection patients
  3. Increased fraction of CD4 central memory T cells in ERS patients, these are decreased close to healthy controls in LRS patients
  4. Increased fraction of plasma cells in ERS patients, decreased in LRS
  5. Class switch of IgA to IgM antibodies happens in the time period from ERS to LRS
  6. Identification of dominant IGV genes in post-COVID-19 patients, this could be useful for vaccine development

Research Impact

For understanding the immune cell composition after clearance of SARS-COV-2 (from PBMCs)

For retrospectively understanding the immune cell response and informing possible vaccine designs/drug targets

For identifying immune signatures in recovery patients


The authors distinguish patients into early recovery stage (n=5, ERS, < 7 days since testing negative for COVID19) and late recovery stage (n=5, LRS, > 14 days) and compared these to healthy controls (n=5)

Single cell RNA-sequencing of PBMCs

scBCR-seq and scTCR-seq to assess clonality of expanded B- and T-cell clones

Computational methods are not well described, therefore some figures are not directly highlighting the conclusions drawn

Some tools used are not standard workflow tools and would need further description in the methods

Strengths and weaknesses of the paper


  • Use of human patients in different stages of disease (healthy controls, ERS and LRS)
  • Robust numbers of patients and healthy controls (5 samples per group; age-matched)
  • Combination of different approaches (scRNA-seq, scTCR-seq and scBCR-seq) for characterising immune cell composition and possible functionality
  • Comparison of ERS to LRS for insights into immune clearance and therapeutic strategy
  • BCR chain occurrence could be important for vaccine development


  • Only recovery patients à ongoing disease for mechanism
  • Only blood, no lung tissue or lung fluid (BAL) à would be important for mechanism proposition
  • Descriptive, no validation of results
  • Computational methods used are not state-of-the-art or not well-described
  • Methods not detailed enough to reproduce the analysis
  • Poorly annotated figures make it difficult to draw conclusions
  • No statistical tests given but findings claimed to be ‘significant’